"Viking Therapeutics' Breakthrough Weight-Loss Drug Challenges Pharma Giants"

Viking Therapeutics' latest weight loss drug trial showed greater efficacy compared to competitors Eli Lilly and Company and Novo Nordisk A/S, positioning the company as a potential acquisition target. The phase II trial demonstrated up to 15% body weight loss with comparable side effects, setting the stage for phase III trials to confirm the results. Despite potential competition from other candidates, the development presents an interesting opportunity in the pharmaceutical industry, particularly for companies like Lilly.